In the News.. A partner for a T1D prevention drug, expanding CGM Medicare coverage, the worst age for T2D outcomes, and more!

It’s It’s “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: Provention Bio hopes to get FDA approval of Teplizumab next month and partners with Sanofi on this T1D prevention drug, new type 2 studies show that younger people who develop it generally have worse…